Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 1-9

  Reck, Martin ^a   Crinò, Lucio ^b  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b Perugia Hospital   (Italy)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Targeted therapies; Treatment paradigms; Vascular endothelial growth factor

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AXITINIB; BEVACIZUMAB; BEXAROTENE; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DEFOROLIMUS; DOCETAXEL; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MOTESANIB; NAVELBINE; OBLIMERSEN; PACLITAXEL; PEMETREXED; PLACEBO; SORAFENIB; SULINDAC SULFONE; SUNITINIB; TEMSIROLIMUS; VANDETANIB; VATALANIB;

ALOPECIA; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; DENDRITIC CELL; DIARRHEA; DRUG FATALITY; DRUG WITHDRAWAL; EPISTAXIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPONATREMIA; INFECTION; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57649093747     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.05.015     Document Type: Review

References (85)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 55 (2005) 74-108
2. Cartman M.L., Hatfield A.C., Muers M.F., Peake M.D., Haward R.A., and Forman D. Lung cancer: district active treatment rates affect survival. J Epidemiol Community Health 56 (2002) 424-429
3. Makitaro R., Paakko P., Huhti E., Bloigu R., and Kinnula V.L. Prospective population-based study on the survival of patients with lung cancer. Eur Respir J 19 (2002) 1087-1092
4. Ginsberg R.J., Vokes E.E., and Rosenzweig K. Non-small cell lung cancer. In: DeVita J.V., Hellman S., and Rosenberg S.A. (Eds). Cancer-principles and practice of oncology (2001), JB Lippincott Co., Philadelphia, PA 925-982
5. Seiwert T.Y., Salama J.K., and Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4 (2007) 86-100
6. Jett J.R., Schild S.E., Keith R.L., and Kesler K.A. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (second edition). Chest 132 3 Suppl. (2007) 266S-276S
7. Socinski M.A., Crowell R., Hensing T.E., Langer C.J., Lilenbaum R., Sandler A.B., et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (second edition). Chest 132 3 Suppl. (2007) S277-S289
8. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker J., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
9. Felip E., Stahel R.A., and Pavlidis N. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 16 Suppl. 1 (2005) 28-29
10. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., and Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292 (2004) 470-484
11. Ardizzoni A., Tiseo M., Boni L., Rosell R., Fossella F.V., Schiller J.H., et al. CISCA (cisplatin vs. carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 24 June 20 Suppl. (2006) 366s [abstract 7011]
12. Tiseo M., and Ardizzoni A. Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review. Oncol Rev 1 (2007) 162-169
13. Gridelli C., and Shepherd F.A. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128 (2005) 947-957
14. Cheong K.A., Chrystal K., and Harper P.G. The management of PS2 patients with advanced non-small cell lung cancer. Int J Clin Pract 60 (2006) 1493-1496
15. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
16. Gronberg B.H., Bremnes R., Aasebo U., Brunsvig P., Flotten O., Hjelde H., et al. Pemetrexed + carboplatin versus gemcitabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 25 June 20 Suppl. (2007) 388s [abstract 7517]
17. Sandler A.B., Johnson D.H., and Herbst R.S. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10 (2004) s4258-s4262
18. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
19. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
20. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 30 3 Suppl. 7 (2003) 3-14
21. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
22. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
23. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
24. Hoffmann-La Roche F. Avastin Summary of Product Characteristics. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/H-582-PI-en.pdf.
25. Manegold C., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Eur J Cancer Suppl 5 4 (2007) 357 [abstract 6503]
26. Manegold C., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25 June 20 Suppl. (2007) 388s [abstract LBA7514]
27. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). J Thoracic Oncol 2 Suppl. 4 (2007) S360 [abstract C1-06]
28. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v.2.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
29. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57 (1997) 4838-4848
30. Yano S., Yamaguchi M., and Dong R.P. EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy. Nippon Yakurigaku Zasshi 122 (2003) 491-497
31. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291 (1999) 739-748
32. Knight L.A., Di N.F., Whitehouse P., Mercer S., Sharma S., Glaysher S., et al. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 4 (2004) 83
33. Giaccone G., Gallegos R.M., Le Chevalier T., Thatcher N., Smit E., Rodriguez J.A., et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12 20 Pt 1 (2006) 6049-6055
34. Jackman D.M., Yeap B.Y., Lindeman N.I., Fidias P., Rabin M.S., Temel J., et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 760-766
35. Paz-Ares L., Sanchez J.M., Garcia-Velasco B., Massuti G., Lopez-Vivanco G., Provencio M., et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 24 June 20 Suppl. (2006) 369s [abstract 7020]
36. Akerley W. Erlotinib as first-line treatment for untreated advanced stage NSCLC with good prognosis. J Clin Oncol 24 June 20 Suppl. (2006) 408s [abstract 7178]
37. Lilenbaum R., Axelrod R., Thomas S., Dowlati A., Seigel L., Albert D., et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 26 (2008) 863-869
38. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25 (2007) 1545-1552
39. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
40. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
41. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
42. Goss G., Ferry D., Laurie S., Wierzbicki R., Thompson J., Biesma B., et al. Randomized, double-blind, multicenter, parallel-group, phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naive patients with advanced non-small cell lung cancer and poor performance status (INSTEP). J Thoracic Oncol 2 Suppl. 4 (2007) S340 [abstract B3-02]
43. Crino L., Zatloukal P., Reck M., Pesek M., Thompson J., Ford H., et al. Gefitinib (IRESSA) versus vinorelbine in chemonaive elderly patients with advanced non-small cell lung cancer (INVITE): a randomized phase II study. J Thoracic Oncol 2 Suppl. 4 (2007) S341 [abstract B3-04]
44. Davies A.M., Ho C., Lara Jr. P.N., Mack P., Gumerlock P.H., and Gandara D.R. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 7 (2006) 385-388
45. Herbst R.S., Chansky K., Kelly K., Atkins J.N., Davies A.M., Dakhil S.R., et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J Clin Oncol 25 June 20 Suppl. (2007) 395s [abstract 7545]
46. Butts C.A., Bodkin D., Middleman E.L., Englund C.W., Ellison D., Alam Y., et al. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25 (2007) 5777-5784
47. ®) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Thoracic Oncol 2 Suppl. 4 (2007) S340 [abstract B3-03]
48. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19 (2008) 362-369
49. Adjei A.A., Molina J., Hillman S.L., Luyun R.F., Reuter N.F., Rowland K.M., et al. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 25 June 20 Suppl. (2007) 396s [abstract 7547]
50. Gatzemeier U., Blumenschein G.R., Fossella F.V., Simantov R., Elting J., Bigwood D., et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24 June 20 Suppl. (2006) 364s [abstract 7002]
51. Scagliotti G, von Pawel J, Reck M, Cupit L, Cihon F, DiMatteo S, et al., Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC) trial. 1st European Lung Cancer Conference 2008 [late breaking abstract].
52. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
53. Schueneman A.J., Himmelfarb E., Geng L., Tan J., Donnelly E., Mendel D., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63 (2003) 4009-4016
54. Laurie S.A., Arnold A., Gauthier I., Chen E., Goss G., Ellis P., et al. Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). J Clin Oncol 24 June 20 Suppl. (2006) 134s [abstract 3054]
55. Heymach J.V., Paz-Ares L., de Braud F., Sebastian M., Stewart D.J., Eberhardt W., et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25 June 20 Suppl. (2007) 395s [abstract 7544]
56. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
57. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18 (2000) 2354-2362
58. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
59. Shepherd F.A., Rodrigues P.J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
60. F Hoffmann-La Roche. Tarceva summary of product characteristics. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/tarceva/H-618-PI-en.pdf.
61. Bezjak A., Tu D., Seymour L., Clark G., Trajkovic A., Zukin M., et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR 21. J Clin Oncol 24 (2006) 3831-3837
62. Perez-Soler R., Delord J.P., Halpern A., Kelly K., Krueger J., Sureda B.M., et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (2005) 345-356
63. Ardizzoni A., Razis E., Lichinitser M., Yilmaz U., Grigorescu A.C., Morero J.L., et al. Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small cell lung cancer (NSCLC). J Thoracic Oncol 2 Suppl. 4 (2007) S342 [abstract B3-06])
64. Smit E., Reck M., Krzakowski M., Gridelli C., Curescu S., Berzinec P., et al. Erlotinib in patients with advanced non-small cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study. Eur J Cancer Suppl 5 (2007) 359 ic
65. Park K., Lee J.S., Wu Y.L., Zhang L., Cheng A., Siu-Kie-Au J., et al. Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRcevalUng cancer Survival Treatment) study of erlotinib for advanced non-small cell lung cancer (NSCLC). J Thoracic Oncol 2 Suppl. 4 (2007) S464 [abstract PD3-2-6]
66. Thatcher N., Chang A., Parikh P., Rodrigues P.J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
67. Douillard J.Y., Kim E., Hirsh V., Mok T., Socinski M.A., Gervais R., et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST). J Thoracic Oncol 2 Suppl. 4 (2007) S305 [abstract PRS-02]
68. Niho S., Ichinose Y., and Tamura T. Results of a randomized phase III study to compare the overall survival of gefitinib versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 25 June 20 Suppl. (2007) 387s [abstract LBA7509]
69. Liu B., Barrett T., Choyke P., Maynard K., Wright J., Kummar S., et al. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 24 June 20 Suppl. (2006) 676s [abstract 17119]
70. Brahmer J.R., Govindan R., Novello S., Rosell R., Belani C.P., Atkins J.N., et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. J Clin Oncol 25 June 20 Suppl. (2007) 395s [abstract 7542]
71. Blumenschein G.R., Robert F., Melnyk O., Sutherland K.C., Tye L., Wang E., et al. Phase II study of erlotinib (E) with or without sunitinib (SU) in the treatment of metastatic non-small cell lung cancer (NSCLC). Eur J Cancer Suppl 5 (2007) 360 [abstract 6511]
72. Gauler T.C., Fischer B., Soria J.C., Gounant V., Griesinger F., Krissel H., et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1, 250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC). J Clin Oncol 24 June 20 Suppl. (2006) 412s [abstract 7195]
73. Crino L., Dansin E., Garrido Lopez P., Griesinger F., Laskin J., Pavlakis N., et al. First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390). Eur J Cancer Suppl 5 (2007) 386 [abstract 6594]
74. Crino L., Dansin E., Garrido Lopez P., Griesinger F., Ko Y.D., Laskin J., et al. MO19390: an open-label safety study of bevacizumab in combination with chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). J Thoracic Oncol 2 Suppl. 4 (2007) S711 [abstract P3-078]
75. Herbst R.S., Johnson D.H., Mininberg E., Carbone D.P., Henderson T., Kim E.S., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 2544-2555
76. Herbst R.S., O'Neill V.J., Fehrenbacher L., Belani C.P., Bonomi P.D., Hart L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25 (2007) 4743-4750
77. Rosell R., Cuello M., Cecere F., Santarpia M., Reguart N., Felip E., et al. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol 18 (2006) 135-143
78. Rosell R., Cecere F., Santarpia M., Reguart N., and Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 6 (2006) 323-331
79. Santarpia M., Altavilla G., Salazar F., Taron M., and Rosell R. From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clin Transl Oncol 8 (2006) 71-76
80. Marchetti A., Felicioni L., and Buttitta F. Assessing EGFR mutations. N Engl J Med 354 (2006) 526-528
81. Tsao M.S., Sakurada A., and Cutz J.C. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
82. Tan E.H., Ramlau R., Pluzanska A., Kuo H.P., Klughammer B., Kockx M., et al. MERIT: a prospective study of putative relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC). J Thoracic Oncol 2 Suppl. 4 (2007) S394 [abstract D2-04]
83. Reck M., Milanowski J., Au S.K., Yang P.C., Akimov M., Duymelinck C., et al. Analysis of possible relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC): data from the prospective MERIT study. Eur J Cancer Suppl 5 (2007) 360 [abstract 6512]
84. Scagliotti G., Purvish P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Thoracic Oncol 2 Suppl. 4 (2007) S306 [abstract PRS-03]
85. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107 (2006) 1589-1596